Clinical Trials Browser

OTHER × Has results × ponatinib × Clear all

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03576547 2025-05-08

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Phase 1/2 Terminated

9 enrolled 11 charts

LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02272998 2025-03-24

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Phase 2 Completed

22 enrolled 13 charts

Neoplasms, Piebaldism

NCT01935336 2022-02-11

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

Phase 2 Completed

171 enrolled 13 charts

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Small Cell Lung Carcinoma

NCT01620216 2021-11-04

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Phase 2 Terminated

12 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02265341 2020-11-25

Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

Phase 2 Completed

12 enrolled 11 charts

Gastrointestinal

Malignant Hepatobiliary Neoplasm

NCT01813734 2019-12-24

Ponatinib in Advanced NSCLC w/ RET Translocations

Phase 2 Completed

9 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02478164 2018-07-24

Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

Phase 2 Completed

17 enrolled 13 charts

CNS

Glioblastoma

NCT01761747 2014-12-23

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

Phase 2/3 Terminated

3 enrolled 9 charts

Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Clinical Trials

Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions

Ponatinib in Advanced NSCLC w/ RET Translocations

Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

Ponatinib for Squamous Cell Lung and Head and Neck Cancers